Klinische Anwendung von Rhopressa: Eine Fallserie

Abstract

Purpose. The aim of this paper is to discuss and highlight via case reports the effective use of Rhopressa in three individual cases of Primary Open-Angle Glaucoma (POAG) treated at a glaucoma clinic in Philadelphia, PA, USA. The cases display the clinical use of netarsudil and reviews therapeutic approach- es to combating the side effects of conjunctival hyperemia associated with netarsudil. Material and Methods. A systematized PubMed literature search based on the terms “Rhopressa”, “netarsudil”, “ROCK inhibition” was conducted. Six eyes of three adult patients were monitored for three months after beginning treatment with Rhopressa (0.02 % netasurdil ophthalmic solution, Aerie Pharmaceuticals Inc, Durham, NC, 2018). Results. In all three cases, an efficacious response was achieved with all three patients obtaining an intraocular pressure of 13 mmHg or lower. In two out of three cases the patients were taking three or more medications prior to the addition of Rhopressa (0.02 % netasurdil ophthalmic solution, Aerie Pharmaceuticals Inc, Durham, NC, 2018). Two eyes out of six possessed a stage of severe glaucoma and two out of six eyes previously underwent multiple surgical glaucoma interventions. Conclusion. A desirable intraocular pressure reduction was found in all six eyes out of three patients with an accept- able tolerability of use of the medication. Rhopressa (0.02 % netasurdil ophthalmic solution, Aerie Pharmaceuticals Inc, Durham, NC, 2018) is a viable and effective adjunct therapy for the treatment of open-angle glaucoma with adequate patient tolerability. Keywords Primary Open Angel Glaucoma (POAG), glaucoma treatment, intraocular pressure, Rhopressa